Today: 11 June 2026
Browse Category

NASDAQ:ASBP 11 November 2025 - 15 December 2025

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma shares fell about 8% to $0.095 on December 15, 2025, as the company’s stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market. Aspire faces Nasdaq deadlines to regain compliance with minimum bid price and equity rules by early 2026. The company is also advancing an FDA regulatory milestone for its sublingual aspirin program.
15 December 2025
·
Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma Holdings (NASDAQ: ASBP) surged over 30% in pre-market trading Friday after announcing a new $100 million equity line of credit with Arena Business Solutions and releasing its Q3 2025 10-Q. Shares traded around $0.14, up from Thursday’s $0.11 close, with market cap near $5.3 million. The new deal replaces a prior ELOC signed in February.
14 November 2025
·
Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

ASBP shares dropped roughly 20–25% mid-session Nov. 11, trading on heavy volume and swinging between $0.1189 and $0.2471. No new company news was released; the last updates were last week’s CPHI Frankfurt partnering recap and special meeting results. Nasdaq delisting risk remains after Aspire requested a hearing to contest compliance failures.
11 November 2025
·

Stock Market Today

  • Telesat (TSAT) Valuation Assessed After Significant Share Price Increase
    June 10, 2026, 7:32 PM EDT. Telesat (TSAT) shares surged 405% over three years but dropped 20% last month, trading at $43.89. The company reports CA$388.3 million revenue with a CA$185.3 million loss. Telesat's Price-to-Sales (P/S) ratio stands at 2.4x, above the US Telecom average of 1.3x and peer average of 2.3x, indicating relatively high investor expectations. However, a regression-based fair P/S of 8.8x suggests the market may undervalue future growth if assumptions hold. Risks include dependence on Geostationary Earth Orbit (GEO) revenue and potential setbacks in Low Earth Orbit (LEO) projects. Investors are advised to weigh the significant potential upside against these operational challenges and market sentiment.

Latest articles

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

11 June 2026
Lloyds shares fell 0.98% as the FCA told Parliament that motor-finance compensation payments are now unlikely before 2027 due to legal challenges, prolonging uncertainty over redress costs and capital returns; investors must wait for clarity, with the next key update due July 30.
Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

11 June 2026
Nokia’s U.S. ADR plunged 3.25% to $13.40, extending losses after a 5.07% drop, as investors reacted to risks from Nvidia’s push into mobile-network tech, raising doubts about Nokia’s role in AI infrastructure and overshadowing new 5G and AI product launches; shares now sit 23% below last week’s high.
Go toTop